Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has closed the second and final tranche of its previously announced private placement offering of its units.
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has entered into an agreement with Research Capital Corporation as the sole agent and sole book-runner on a
September 1, 2023 (Investorideas.com Newswire) investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potc...
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the results of a clinical...
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company specializing...
Innocan Pharma Corporation is pleased to announce its been engaged into a manufacturing and distribution agreement dated August, 2021 with Ayurcann Inc. , a major Health Canada licensed producer... | August 11, 2021
HERZLIYA, Israel and CALGARY, Alberta, June 21, 2021 (GLOBE NEWSWIRE) — Innocan Pharma (OTC: INNPF) (CSE: INNO) (FSE: IP4) based in Israel, focused on…
HERZLIYA, Israel and CALGARY, Alberta, June 21, 2021 -- Innocan Pharma based in Israel, focused on developing drug delivery platforms containing Cannabinoids today announced that...